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INTRODUCTION
Epithelial ovarian cancer (EOC), which accounts for 90% of ovarian cancer, is a heterogeneous disease divided into histologic subtypes: serous, mucinous, endometrioid, clear cell, Brenner, and undifferentiated carcinomas. The serous type represents 75% -80% of EOCs and accounts for the majority of deaths from gynecological malignancies (1-4). Even with optimal treatment consisting of surgical cytoreduction (debulking) followed by platinum and taxane-based chemotherapy, the 5-year survival for women with advanced stage disease is only 46% at best (5). Currently there is no molecularly targeted therapy for ovarian cancer, and over 50% of women with tumor that respond to initial treatment relapse within 18 to 24 months (5). In ovarian cancer, metastasis primarily occurs by a mechanism termed direct seeding, which involves shedding of tumor cells from the primary site into the peritoneal cavity. For this journey, ovarian cancer cells must acquire resistance to anoikis (apoptosis initiated upon loss of attachment to native extracellular matrix) to allow survival in suspension in ascitic fluid before attaching to the peritoneum. A targeted therapy that could reduce tumor burden by simultaneously affecting multiple factors critical for ovarian cancer progression such as anoikis resistance, chemoresistance and attachment to sites in the peritoneal cavity would be a revolutionary breakthrough for this aggressive gynecologic malignancy.
A recent study demonstrated that micro-RNA 200c (miR-200c) targets ZEB1 and ZEB2 in ovarian cancer cells and thereby restores E-cadherin and reduces motility (6). Author Manuscript Published OnlineFirst on October 16, 2012; DOI: 10.1158 /1535 Ͷ ovarian cancer cells (7, 8) . TUBB3 is not expressed in normal epithelial cells, but is often overexpressed in clinical specimens and cell lines of taxane-resistant carcinomas (9) (10) (11) (12) including ovarian cancer (13, 14) . Indeed TUBB3 expression is considered to be one of the main mechanisms of resistance to taxanes in general in many types of carcinomas (9) and in ovarian cancer (13) (14) (15) (16) . The mechanism by which overexpression of TUBB3 is thought to result in resistance to taxanes is by enhancement of the dynamic instability of microtubules, thereby counteracting the activity of microtubule targeting agents. A recent study suggests additional novel mechanisms by which TUBB3 contributes to drug resistance (17).
Another important direct target of miR-200c that we recently identified is NTRK2, the gene encoding TrkB (18) a tyrosine kinase receptor normally expressed in neurons, but co-opted by various types of cancer including ovarian cancer to achieve anoikis resistance (19-23). Since chemo-and anoikis resistance represent critical steps in ovarian cancer progression, we sought to determine how restoration of miR-200c would affect ovarian cancer tumor burden and chemosensitivity in vivo. Here we demonstrate that restoration of miR-200c to ovarian cancer cell lines enhances anoikis sensitivity, decreases attachment to biological substrates, decreases tumor burden and enhances chemosensitivity in vitro and in vivo. Western blot and protein expression quantification. Total cell lysates were prepared and analyzed by western blot exactly as described elsewhere [12] . Primary antibodies used for western blot included mouse-monoclonal anti-ȕ-III-tubulin (Sigma-Aldrich, St.
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Louis, MO, 1:1000 dilution); mouse monoclonal anti Į-tubulin (Sigma-Aldrich, St.
Louis, MO, USA, clone B-5-1-2, 1:30,000); rabbit polyclonal anti-ZEB1 (from Dr. Doug Darling, University of Louisville, Louisville, KY, USA; 1:1,500 dilution). Secondary antibodies were Alexa-fluor 680 Conjugated Affinity Purified Anti-Rabbit or Anti-Mouse IgG (Invitrogen, Garland, CA) detected using an Odyssey Infrared Imaging System (Licor Biosciences, Lincoln, NE). Bands at the expected molecular weights were cropped for presentation purposes and independent blots are shown surrounded by black boxes.
Protein levels were measured by obtaining the integrated intensity of the target band relative to the integrated intensity of a loading control (i.e. Į-tubulin) using the Odyssey quantification tools.
Anoikis assays. Poly-hydroxyethyl methacrylate (poly-HEMA, Sigma-Aldrich) was reconstituted in 95% ethanol to a concentration of 12 mg/mL. To prepare poly-HEMA coated plates, 0.5 mL of 12 mg/mL solution was added to each well of a 24-well plate and allowed to dry overnight in a laminar flow tissue culture hood. Cells were transfected with transfection reagent alone, 50nM negative control or 50nM miR-200c mimics.
Twenty-four hours later, 50,000 cells were plated in poly-HEMA coated 24-well plates in the presence of 10ȝM EDTA. Media was collected at 8, 24 and 48 hr and floating cells were pelleted and lysed for apoptosis analyses. For the inducible miR-200c system, the pTRIPz-200c cells were pre-treated with 1ȝg/ml dox for 24h, then plated (15,000 cells/well) in 96-well plates in either adherent or suspension conditions. After 24h, cells were pelleted and lysed. Apoptosis was measured using the cell death ELISA kit (Roche) following manufacturer instructions. Life technologies, NJ) as described by the manufacturer. RNU6 was used for normalization. At least 3 biological replicates and triplicate PCRs were used to calculate relative expression. he relative mRNA or miRNA levels were calculated using the comparative Ct method (ǻǻCt). Briefly, the Ct (cycle threshold) values for the normalization gene were subtracted from Ct values of the target gene to achieve the ǻCt value. The 2íǻCt was calculated for each sample and then each of the values was divided by a control sample to achieve the relative mRNA or miRNA levels (ǻǻCt). Student's t-tests (two groups) or ANOVA followed by Tukey post hoc test (three or more groups) were used. Results with P<0.05 were considered statistically significant. 
RESULTS
Restoration of miR-200c to ovarian cancer cells increases anoikis
